Quick Answer
BiomX Inc. reported Operating Income Loss of -$41.47 million for the year ending 2025.
- BiomX Inc. showed an increase of +6.9% in Operating Income Loss from 2024 to 2025.
- This data is from BiomX Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$1.0 thousand | Q3 2018: -$650.00 | Q4 2018: -$15.8 thousand | Q1 2019: -$3.72 million | Q2 2019: -$4.07 million | Q3 2019: -$4.66 million | Q1 2020: -$5.97 million | Q2 2020: -$6.39 million | Q3 2020: -$8.83 million | Q1 2021: -$8.54 million | Q2 2021: -$7.30 million | Q3 2021: -$9.83 million | Q1 2022: -$7.79 million | Q2 2022: -$7.32 million | Q3 2022: -$6.55 million | Q1 2023: -$6.21 million | Q2 2023: -$6.07 million | Q3 2023: -$7.80 million | Q1 2024: -$6.79 million | Q2 2024: -$9.73 million | Q3 2024: -$11.33 million | Q1 2025: -$7.76 million | Q2 2025: -$7.43 million | Q3 2025: -$8.54 million.
- Over the full 9 years of available data (2018 to 2025), BiomX Inc.'s Operating Income Loss has declined by 231.9%.
- Historical annual values: Fiscal year 2025: -$41.47 million | Fiscal year 2024: -$44.52 million | Fiscal year 2023: -$25.35 million | Fiscal year 2022: -$27.22 million | Fiscal year 2021: -$35.46 million | Fiscal year 2020: -$30.26 million | Fiscal year 2019: -$22.21 million | Fiscal year 2019: -$404.5 thousand | Fiscal year 2018: -$12.50 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: